Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 7/2009

01-07-2009 | Original Article

FDG PET imaging of Ela1-myc mice reveals major biological differences between pancreatic acinar and ductal tumours

Authors: Ibane Abasolo, Judit Pujal, Rosa M. Rabanal, Anna Serafin, Pilar Navarro, Olga Millán, Francisco X. Real

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2009

Login to get access

Abstract

Purpose

The aim was to evaluate FDG PET imaging in Ela1-myc mice, a pancreatic cancer model resulting in the development of tumours with either acinar or mixed acinar-ductal phenotype.

Methods

Transversal and longitudinal FDG PET studies were conducted; selected tissue samples were subjected to autoradiography and ex vivo organ counting. Glucose transporter and hexokinase mRNA expression was analysed by quantitative reverse transcription polymerase chain reaction (RT-PCR); Glut2 expression was analysed by immunohistochemistry.

Results

Transversal studies showed that mixed acinar-ductal tumours could be identified by FDG PET several weeks before they could be detected by hand palpation. Longitudinal studies revealed that ductal—but not acinar—tumours could be detected by FDG PET. Autoradiographic analysis confirmed that tumour areas with ductal differentiation incorporated more FDG than areas displaying acinar differentiation. Ex vivo radioactivity measurements showed that tumours of solely acinar phenotype incorporated more FDG than pancreata of non-transgenic littermates despite the fact that they did not yield positive PET images. To gain insight into the biological basis of the differential FDG uptake, glucose transporter and hexokinase transcript expression was studied in microdissected tumour areas enriched for acinar or ductal cells and validated using cell-specific markers. Glut2 and hexokinase I and II mRNA levels were up to 20-fold higher in ductal than in acinar tumours. Besides, Glut2 protein overexpression was found in ductal neoplastic cells but not in the surrounding stroma.

Conclusion

In Ela1-myc mice, ductal tumours incorporate significantly more FDG than acinar tumours. This difference likely results from differential expression of Glut2 and hexokinases. These findings reveal previously unreported biological differences between acinar and ductal pancreatic tumours.
Literature
1.
go back to reference DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999;117:1464–84.PubMedCrossRef DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999;117:1464–84.PubMedCrossRef
2.
go back to reference Real FX. A “catastrophic hypothesis” for pancreas cancer progression. Gastroenterology 2003;124:1958–64.PubMedCrossRef Real FX. A “catastrophic hypothesis” for pancreas cancer progression. Gastroenterology 2003;124:1958–64.PubMedCrossRef
3.
go back to reference Chin BB, Chang PP. Gastrointestinal malignancies evaluated with (18)F-fluoro-2-deoxyglucose positron emission tomography. Best Pract Res Clin Gastroenterol 2006;20:3–21.PubMedCrossRef Chin BB, Chang PP. Gastrointestinal malignancies evaluated with (18)F-fluoro-2-deoxyglucose positron emission tomography. Best Pract Res Clin Gastroenterol 2006;20:3–21.PubMedCrossRef
4.
go back to reference Delbeke D, Pinson CW. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg 2004;11:4–10.PubMedCrossRef Delbeke D, Pinson CW. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg 2004;11:4–10.PubMedCrossRef
5.
go back to reference Aguilar S, Corominas JM, Malats N, Pereira JA, Dufresne M, Real FX, et al. Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumors and contribution to cancer progression. Am J Pathol 2004;165:1129–39.PubMed Aguilar S, Corominas JM, Malats N, Pereira JA, Dufresne M, Real FX, et al. Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumors and contribution to cancer progression. Am J Pathol 2004;165:1129–39.PubMed
6.
go back to reference Sandgren EP, Quaife CJ, Paulovich AG, Palmiter RD, Brinster RL. Pancreatic tumor pathogenesis reflects the causative genetic lesion. Proc Natl Acad Sci USA 1991;88:93–7.PubMedCrossRef Sandgren EP, Quaife CJ, Paulovich AG, Palmiter RD, Brinster RL. Pancreatic tumor pathogenesis reflects the causative genetic lesion. Proc Natl Acad Sci USA 1991;88:93–7.PubMedCrossRef
7.
go back to reference Liao DJ, Wang Y, Wu J, Adsay NV, Grignon D, Khanani F, et al. Characterization of pancreatic lesions from MT-tgf alpha, Ela-myc and MT-tgf alpha/Ela-myc single and double transgenic mice. J Carcinog 2006;5:19.PubMedCrossRef Liao DJ, Wang Y, Wu J, Adsay NV, Grignon D, Khanani F, et al. Characterization of pancreatic lesions from MT-tgf alpha, Ela-myc and MT-tgf alpha/Ela-myc single and double transgenic mice. J Carcinog 2006;5:19.PubMedCrossRef
8.
go back to reference Thorens B. Molecular and cellular physiology of Glut-2, a high-Km facilitated diffusion glucose transporter. Int Rev Cytol 1992;137:209–38.PubMedCrossRef Thorens B. Molecular and cellular physiology of Glut-2, a high-Km facilitated diffusion glucose transporter. Int Rev Cytol 1992;137:209–38.PubMedCrossRef
9.
go back to reference Smith TAD. The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation. Nucl Med Biol 2001;28:1–4.PubMedCrossRef Smith TAD. The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation. Nucl Med Biol 2001;28:1–4.PubMedCrossRef
10.
go back to reference Hernández-Muñoz I, Skoudy A, Real FX, Navarro P. Pancreatic ductal adenocarcinoma: cellular origin, signaling pathways and stroma contribution. Pancreatology 2008;8:462–9.PubMedCrossRef Hernández-Muñoz I, Skoudy A, Real FX, Navarro P. Pancreatic ductal adenocarcinoma: cellular origin, signaling pathways and stroma contribution. Pancreatology 2008;8:462–9.PubMedCrossRef
11.
go back to reference Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Mazière B. FDG accumulation and tumor biology. Nucl Med Biol 1998;25:317–22.PubMedCrossRef Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Mazière B. FDG accumulation and tumor biology. Nucl Med Biol 1998;25:317–22.PubMedCrossRef
12.
go back to reference Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (Glut) proteins in cancer. J Cell Physiol 2005;202:654–62.PubMedCrossRef Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (Glut) proteins in cancer. J Cell Physiol 2005;202:654–62.PubMedCrossRef
13.
go back to reference Smith TA. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci 2000;57:170–8.PubMed Smith TA. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci 2000;57:170–8.PubMed
14.
go back to reference Nakata B, Nishimura S, Ishikawa T, Ohira M, Nishino H, Kawabe J, et al. Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int J Oncol 2001;19:53–8.PubMed Nakata B, Nishimura S, Ishikawa T, Ohira M, Nishino H, Kawabe J, et al. Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int J Oncol 2001;19:53–8.PubMed
15.
go back to reference Zimny M, Fass J, Bares R, Cremerius U, Sabri O, Buechin P, et al. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. Scand J Gastroenterol 2000;35:883–8.PubMedCrossRef Zimny M, Fass J, Bares R, Cremerius U, Sabri O, Buechin P, et al. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. Scand J Gastroenterol 2000;35:883–8.PubMedCrossRef
16.
go back to reference Seitz U, Wagner M, Vogg AT, Glatting G, Neumaier B, Greten FR, et al. In vivo evaluation of 5-[(18)F]fluoro-2′-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model. Cancer Res 2001;61:3853–7.PubMed Seitz U, Wagner M, Vogg AT, Glatting G, Neumaier B, Greten FR, et al. In vivo evaluation of 5-[(18)F]fluoro-2′-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model. Cancer Res 2001;61:3853–7.PubMed
17.
go back to reference Buck AC, Schirrmeister HH, Guhlmann CA, Diederichs CG, Shen C, Buchmann I, et al. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med 2001;42:721–5.PubMed Buck AC, Schirrmeister HH, Guhlmann CA, Diederichs CG, Shen C, Buchmann I, et al. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med 2001;42:721–5.PubMed
18.
go back to reference Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007;11:291–302.PubMedCrossRef Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007;11:291–302.PubMedCrossRef
19.
go back to reference Knoess C, Siegel S, Smith A, Newport D, Richerzhagen N, Winkeler A, et al. Performance evaluation of the microPET R4 PET scanner for rodents. Eur J Nucl Med Mol Imaging 2003;30:737–47.PubMed Knoess C, Siegel S, Smith A, Newport D, Richerzhagen N, Winkeler A, et al. Performance evaluation of the microPET R4 PET scanner for rodents. Eur J Nucl Med Mol Imaging 2003;30:737–47.PubMed
20.
go back to reference Phelps ME, editor. PET molecular imaging and its biological applications. New York: Springer; 2004. Phelps ME, editor. PET molecular imaging and its biological applications. New York: Springer; 2004.
21.
go back to reference van Kouwen MC, Laverman P, van Krieken JH, Oyen WJ, Jansen JB, Drenth JP. FDG-PET in the detection of early pancreatic cancer in a BOP hamster model. Nucl Med Biol 2005;32:445–50.PubMedCrossRef van Kouwen MC, Laverman P, van Krieken JH, Oyen WJ, Jansen JB, Drenth JP. FDG-PET in the detection of early pancreatic cancer in a BOP hamster model. Nucl Med Biol 2005;32:445–50.PubMedCrossRef
22.
go back to reference Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kimura T, et al. FDG uptake, Glut-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998;39:1727–35.PubMed Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kimura T, et al. FDG uptake, Glut-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998;39:1727–35.PubMed
23.
go back to reference von Forstner C, Egberts JH, Ammerpohl O, Niedzielska D, Buchert R, Mikecz P, et al. Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer. J Nucl Med 2008;49:1362–70.CrossRef von Forstner C, Egberts JH, Ammerpohl O, Niedzielska D, Buchert R, Mikecz P, et al. Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer. J Nucl Med 2008;49:1362–70.CrossRef
24.
go back to reference Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379–87.PubMedCrossRef Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379–87.PubMedCrossRef
25.
go back to reference Hooft L, van der Veldt AA, van Diest PJ, Hoekstra OS, Berkhof J, Teule GJ, et al. [18F]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase i expression in the primary tumor. J Clin Endocrinol Metab 2005;90:328–34.PubMedCrossRef Hooft L, van der Veldt AA, van Diest PJ, Hoekstra OS, Berkhof J, Teule GJ, et al. [18F]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase i expression in the primary tumor. J Clin Endocrinol Metab 2005;90:328–34.PubMedCrossRef
26.
go back to reference Natsuizaka M, Ozasa M, Darmanin S, Miyamoto M, Kondo S, Kamada S, et al. Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. Exp Cell Res 2007;313:3337–48.PubMedCrossRef Natsuizaka M, Ozasa M, Darmanin S, Miyamoto M, Kondo S, Kamada S, et al. Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. Exp Cell Res 2007;313:3337–48.PubMedCrossRef
27.
go back to reference Yoon DY, Buchler P, Saarikoski ST, Hines OJ, Reber HA, Hankinson O. Identification of genes differentially induced by hypoxia in pancreatic cancer cells. Biochem Biophys Res Commun 2001;288:882–6.PubMedCrossRef Yoon DY, Buchler P, Saarikoski ST, Hines OJ, Reber HA, Hankinson O. Identification of genes differentially induced by hypoxia in pancreatic cancer cells. Biochem Biophys Res Commun 2001;288:882–6.PubMedCrossRef
28.
go back to reference Mikuriya K, Kuramitsu Y, Ryozawa S, Fujimoto M, Mori S, Oka M, et al. Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol 2007;30:849–55.PubMed Mikuriya K, Kuramitsu Y, Ryozawa S, Fujimoto M, Mori S, Oka M, et al. Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol 2007;30:849–55.PubMed
29.
go back to reference Hingorani SR. New pathways to pancreatic cancer. Cancer Biol Ther 2004;3:170–2.PubMed Hingorani SR. New pathways to pancreatic cancer. Cancer Biol Ther 2004;3:170–2.PubMed
30.
31.
go back to reference Tuveson DA, Hingorani SR. Ductal pancreatic cancer in humans and mice. Cold Spring Harb Symp Quant Biol 2005;70:65–72.PubMedCrossRef Tuveson DA, Hingorani SR. Ductal pancreatic cancer in humans and mice. Cold Spring Harb Symp Quant Biol 2005;70:65–72.PubMedCrossRef
32.
go back to reference Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437–50.PubMedCrossRef Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437–50.PubMedCrossRef
33.
go back to reference Nitzsche EU, Hoegerle S, Mix M, Brink I, Otte A, Moser E, et al. Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis? Eur J Nucl Med Mol Imaging 2002;29:237–42.PubMedCrossRef Nitzsche EU, Hoegerle S, Mix M, Brink I, Otte A, Moser E, et al. Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis? Eur J Nucl Med Mol Imaging 2002;29:237–42.PubMedCrossRef
34.
go back to reference Real FX, Cibrián-Uhalte E, Martinelli P. Pancreatic cancer development and progression: remodeling the model. Gastroenterology 2008;135:724–8.PubMedCrossRef Real FX, Cibrián-Uhalte E, Martinelli P. Pancreatic cancer development and progression: remodeling the model. Gastroenterology 2008;135:724–8.PubMedCrossRef
Metadata
Title
FDG PET imaging of Ela1-myc mice reveals major biological differences between pancreatic acinar and ductal tumours
Authors
Ibane Abasolo
Judit Pujal
Rosa M. Rabanal
Anna Serafin
Pilar Navarro
Olga Millán
Francisco X. Real
Publication date
01-07-2009
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-009-1083-3

Other articles of this Issue 7/2009

European Journal of Nuclear Medicine and Molecular Imaging 7/2009 Go to the issue